These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 9116394)

  • 21. Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial.
    Monegal A; Guañabens N; Suárez MJ; Suárez F; Clemente G; García-González M; De la Mata M; Serrano T; Casafont F; Tome S; Barrios C; Navasa M
    Transpl Int; 2009 Feb; 22(2):198-206. PubMed ID: 18796000
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A longitudinal study of supine lateral DXA of the lumbar spine: a comparison with posteroanterior spine, hip and total-body DXA.
    Blake GM; Herd RJ; Fogelman I
    Osteoporos Int; 1996; 6(6):462-70. PubMed ID: 9116392
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mineral density gain in vertebrae of osteoporotic women on oral pamidronate reverts a year after treatment discontinuance.
    Zanchetta JR; Plotkin H; Roldán EJ
    Calcif Tissue Int; 1996 Jul; 59(1):70-2. PubMed ID: 8661988
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention of osteoporosis in heart transplant recipients: a comparison of calcitriol with calcitonin and pamidronate.
    Bianda T; Linka A; Junga G; Brunner H; Steinert H; Kiowski W; Schmid C
    Calcif Tissue Int; 2000 Aug; 67(2):116-21. PubMed ID: 10920215
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravenous pamidronate compared with oral alendronate for the treatment of postmenopausal osteoporosis.
    Heijckmann AC; Juttmann JR; Wolffenbuttel BH
    Neth J Med; 2002 Sep; 60(8):315-9. PubMed ID: 12481878
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevention of bone loss by clodronate in early postmenopausal women with vertebral osteopenia: a dose-finding study.
    Välimäki MJ; Laitinen K; Patronen A; Puolijoki H; Seppänen J; Pylkkänen L; Aranko SM; Sairanen S; Blåfield H; Rekiaro M; Väisänen K; Kormano M; Mäkinen L; Salmi J; Ala-Kaila K; Perttilä J; Vesterinen K; Koivunoro K;
    Osteoporos Int; 2002 Dec; 13(12):937-47. PubMed ID: 12459936
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women.
    Stakkestad JA; Benevolenskaya LI; Stepan JJ; Skag A; Nordby A; Oefjord E; Burdeska A; Jonkanski I; Mahoney P;
    Ann Rheum Dis; 2003 Oct; 62(10):969-75. PubMed ID: 12972476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pamidronate increases bone mineral density in women with postmenopausal or steroid-induced osteoporosis.
    Cauza E; Etemad M; Winkler F; Hanusch-Enserer U; Partsch G; Noske H; Dunky A
    J Clin Pharm Ther; 2004 Oct; 29(5):431-6. PubMed ID: 15482386
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension.
    Brumsen C; Papapoulos SE; Lips P; Geelhoed-Duijvestijn PH; Hamdy NA; Landman JO; McCloskey EV; Netelenbos JC; Pauwels EK; Roos JC; Valentijn RM; Zwinderman AH
    J Bone Miner Res; 2002 Jun; 17(6):1057-64. PubMed ID: 12054161
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial.
    Hooper MJ; Ebeling PR; Roberts AP; Graham JJ; Nicholson GC; D'Emden M; Ernst TF; Wenderoth D
    Climacteric; 2005 Sep; 8(3):251-62. PubMed ID: 16390757
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention of early postmenopausal bone loss with cyclical etidronate.
    Adami S; Bruni V; Bianchini D; Becorpi A; Lombardi P; Campagnoli C; Ferrari A; Marchesoni T; Balena R
    J Endocrinol Invest; 2000 May; 23(5):310-6. PubMed ID: 10882149
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effectiveness of cyclic and continuous oral clodronate therapy on bone density and markers in osteopenic postmenopausal women.
    Tsai KS; Hsu SH; Yang RS; Cheng WC; Chieng PU
    Calcif Tissue Int; 1999 May; 64(5):384-8. PubMed ID: 10203414
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss.
    McClung MR; Bolognese MA; Sedarati F; Recker RR; Miller PD
    Bone; 2009 Mar; 44(3):418-22. PubMed ID: 18950736
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
    Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S
    Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study.
    Eisman JA; Civitelli R; Adami S; Czerwinski E; Recknor C; Prince R; Reginster JY; Zaidi M; Felsenberg D; Hughes C; Mairon N; Masanauskaite D; Reid DM; Delmas PD; Recker RR
    J Rheumatol; 2008 Mar; 35(3):488-97. PubMed ID: 18260172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin.
    Adami S; Baroni MC; Broggini M; Carratelli L; Caruso I; Gnessi L; Laurenzi M; Lombardi A; Norbiato G; Ortolani S
    Osteoporos Int; 1993; 3 Suppl 3():S21-7. PubMed ID: 8298199
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study.
    Delmas PD; Balena R; Confravreux E; Hardouin C; Hardy P; Bremond A
    J Clin Oncol; 1997 Mar; 15(3):955-62. PubMed ID: 9060533
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Cyclic intravenous pamidronate in treatment of osteoporosis].
    Vujasinović-Stupar N; Pilipović N; Branković S
    Med Pregl; 2004; 57(11-12):545-50. PubMed ID: 16107000
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The benefit of hormone replacement therapy on bone mass is greater at the vertebral body than posterior processes or proximal femur.
    Duan Y; Tabensky A; DeLuca V; Seeman E
    Bone; 1997 Nov; 21(5):447-51. PubMed ID: 9356739
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term change in the bone mineral density of adults with adult onset growth hormone (GH) deficiency in response to short or long-term GH replacement therapy.
    Rahim A; Holmes SJ; Adams JE; Shalet SM
    Clin Endocrinol (Oxf); 1998 Apr; 48(4):463-9. PubMed ID: 9640413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.